| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2021-09-11 17:09:19 UTC |
|---|
| Update Date | 2022-11-23 21:39:02 UTC |
|---|
| HMDB ID | HMDB0256624 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | 2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide |
|---|
| Description | N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE, also known as 2-(dimethylamino)-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)acetamide or 2-(dimethylaminoacetylamino)-5,6-dihydrophenanthridine-6-one, belongs to the class of organic compounds known as phenanthridines and derivatives. These are polycyclic compounds containing a phenanthridine moiety, which is a tricyclic system with two benzene rings joined by a pyridine forming a non-linear skeleton. Hydrogenated derivatives are also included. Based on a literature review a significant number of articles have been published on N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE. This compound has been identified in human blood as reported by (PMID: 31557052 ). 2-(dimethylamino)-n-(6-oxo-5h-phenanthridin-2-yl)acetamide is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically 2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
|---|
| Structure | CN(C)CC(=O)NC1=CC2=C(NC(=O)C3=CC=CC=C23)C=C1 InChI=1S/C17H17N3O2/c1-20(2)10-16(21)18-11-7-8-15-14(9-11)12-5-3-4-6-13(12)17(22)19-15/h3-9H,10H2,1-2H3,(H,18,21)(H,19,22) |
|---|
| Synonyms | | Value | Source |
|---|
| 2-(Dimethylamino)-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)acetamide | ChEBI | | 2-(Dimethylaminoacetylamino)-5,6-dihydrophenanthridine-6-one | ChEBI | | N-(5,6-Dihydro-6-oxo-2-phenanthridinyl)-2-(dimethylamino)acetamide | ChEBI | | N-(5,6-Dihydro-6-oxophenanthridine-2-yl)-2-(dimethylamino)acetamide | ChEBI | | N(2),N(2)-Dimethyl-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)glycinamide | ChEBI | | PJ 34 | ChEBI | | PJ-34 | ChEBI | | N-(oxo-5,6-Dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride | MeSH | | 2-(Dimethylamino)-N-(6-hydroxyphenanthridin-2-yl)ethanimidate | Generator |
|
|---|
| Chemical Formula | C17H17N3O2 |
|---|
| Average Molecular Weight | 295.3358 |
|---|
| Monoisotopic Molecular Weight | 295.132076803 |
|---|
| IUPAC Name | 2-(dimethylamino)-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)acetamide |
|---|
| Traditional Name | 2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CN(C)CC(=O)NC1=CC2=C(NC(=O)C3=CC=CC=C23)C=C1 |
|---|
| InChI Identifier | InChI=1S/C17H17N3O2/c1-20(2)10-16(21)18-11-7-8-15-14(9-11)12-5-3-4-6-13(12)17(22)19-15/h3-9H,10H2,1-2H3,(H,18,21)(H,19,22) |
|---|
| InChI Key | UYJZZVDLGDDTCL-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenanthridines and derivatives. These are polycyclic compounds containing a phenanthridine moiety, which is a tricyclic system with two benzene rings joined by a pyridine forming a non-linear skeleton. Hydrogenated derivatives are also included. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Quinolines and derivatives |
|---|
| Sub Class | Benzoquinolines |
|---|
| Direct Parent | Phenanthridines and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Phenanthridine
- Alpha-amino acid amide
- Dihydroquinolone
- Isoquinolone
- Alpha-amino acid or derivatives
- Dihydroquinoline
- Isoquinoline
- N-arylamide
- Pyridinone
- Pyridine
- Benzenoid
- Heteroaromatic compound
- Secondary carboxylic acid amide
- Tertiary aliphatic amine
- Tertiary amine
- Amino acid or derivatives
- Carboxamide group
- Lactam
- Azacycle
- Carboxylic acid derivative
- Organic oxygen compound
- Organic oxide
- Organopnictogen compound
- Hydrocarbon derivative
- Organonitrogen compound
- Carbonyl group
- Organooxygen compound
- Amine
- Organic nitrogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. | 3.56 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.7438 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.22 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 847.2 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 235.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 110.0 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 177.7 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 56.1 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 263.7 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 331.6 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 534.1 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 565.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 65.6 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 857.6 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 205.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 254.4 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 466.6 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 571.9 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 54.8 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TMS,isomer #1 | CN(C)CC(=O)N(C1=CC=C2[NH]C(=O)C3=CC=CC=C3C2=C1)[Si](C)(C)C | 2750.3 | Semi standard non polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TMS,isomer #1 | CN(C)CC(=O)N(C1=CC=C2[NH]C(=O)C3=CC=CC=C3C2=C1)[Si](C)(C)C | 2875.7 | Standard non polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TMS,isomer #1 | CN(C)CC(=O)N(C1=CC=C2[NH]C(=O)C3=CC=CC=C3C2=C1)[Si](C)(C)C | 3468.6 | Standard polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TMS,isomer #2 | CN(C)CC(=O)NC1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C | 2964.6 | Semi standard non polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TMS,isomer #2 | CN(C)CC(=O)NC1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C | 2898.5 | Standard non polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TMS,isomer #2 | CN(C)CC(=O)NC1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C | 3586.8 | Standard polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,2TMS,isomer #1 | CN(C)CC(=O)N(C1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C)[Si](C)(C)C | 2750.0 | Semi standard non polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,2TMS,isomer #1 | CN(C)CC(=O)N(C1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C)[Si](C)(C)C | 2880.5 | Standard non polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,2TMS,isomer #1 | CN(C)CC(=O)N(C1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C)[Si](C)(C)C | 3147.6 | Standard polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TBDMS,isomer #1 | CN(C)CC(=O)N(C1=CC=C2[NH]C(=O)C3=CC=CC=C3C2=C1)[Si](C)(C)C(C)(C)C | 3011.7 | Semi standard non polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TBDMS,isomer #1 | CN(C)CC(=O)N(C1=CC=C2[NH]C(=O)C3=CC=CC=C3C2=C1)[Si](C)(C)C(C)(C)C | 3050.6 | Standard non polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TBDMS,isomer #1 | CN(C)CC(=O)N(C1=CC=C2[NH]C(=O)C3=CC=CC=C3C2=C1)[Si](C)(C)C(C)(C)C | 3516.8 | Standard polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TBDMS,isomer #2 | CN(C)CC(=O)NC1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C(C)(C)C | 3168.0 | Semi standard non polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TBDMS,isomer #2 | CN(C)CC(=O)NC1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C(C)(C)C | 3059.1 | Standard non polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TBDMS,isomer #2 | CN(C)CC(=O)NC1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C(C)(C)C | 3607.4 | Standard polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,2TBDMS,isomer #1 | CN(C)CC(=O)N(C1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3217.7 | Semi standard non polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,2TBDMS,isomer #1 | CN(C)CC(=O)N(C1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3235.9 | Standard non polar | 33892256 | | N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,2TBDMS,isomer #1 | CN(C)CC(=O)N(C1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3314.5 | Standard polar | 33892256 |
|
|---|